Article Listing - Revenues in 1st-qtr rise 30% at Shire
SELF-MEDICATION IN EUROPE IN THE 1990s
23 March 1992
The criteria for success for companies marketing self-medication pharmaceutical products in Europe will change fundamentally over the next three years,...
US APPRO OF J&J's HEP C TEST
23 March 1992
The US Food and Drug Administr-ation has licensed Johnson and Johnson's new sensitive blood screening test for the hepatitis C...
UK MARKETING OF MAXEPA
23 March 1992
The only prescription formulation of the fish oil-derived omega-3 fatty acid product Maxepa is to be marketed in the UK...
GENETIC IMMUNIZATION ADVANCE
23 March 1992
The new technique of genetic immunization could represent a time- and labor-saving means of eliciting antibodies and it could offer...
HOW EC PATENT EXTENSION IS SHAPING UP
23 March 1992
Last week, the Council of the Commission of the European Communities passed to the Europ-ean Parliament its common position on...
FROM A RESEARCH-LED TO A MARKET-DRIVEN FIRM
23 March 1992
The task of pharmaceutical industry management is to achieve the best possible balance between the constant pull of the...
ARGENTINE GENERICS POLICY CHANGE
23 March 1992
Having established at the beginning of 1992 a generics policy which required doctors to prescribe medicines using generic names only,...
CHILE COMPLETES ITS PATENT LAWS REFORMS
23 March 1992
One of the many features which differentiate the Chilean pharmaceutical sector from that of other Latin American countries is that...
US FDA "SHOULD BAN SPEAKER LISTS"
23 March 1992
Among the views presented to the US Food and Drug Administra-tion on its proposed draft guideline on Drug Company-Sponsored Activities...
US PRESCRIPTION PRICES UP 8.1%IN 1991
23 March 1992
Prescription prices in the USA increased by 8.1% last year to an average of $14.75 at pharmacy acquisition prices, compared...
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
